RIPOR family member 3Genealiases: C20orf175 · C20orf176 · FAM65C
Q-omics provides the consensus-scored RIPOR3 profile across patient tissues and cancer cell-line models. RIPOR3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RIPOR3 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, RIPOR3 RNA expression shows 17,986 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRP, and UVM as cancer lineages where RIPOR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIPOR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIPOR3 survival associations across molecular data types. RIPOR3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIPOR3 RNA expression–survival associations across cancer types. High RIPOR3 expression shows unfavorable associations in LGG, but favorable associations in HNSC, UCEC, KIRC, BRCA and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RIPOR3 RNA expression.
This table summarizes RIPOR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RIPOR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIPOR3 shows lower tumor expression in KIRP, KICH, THCA, LIHC and KIRC and higher tumor expression in HNSC. The KIRP box plot shows higher RIPOR3 RNA expression in normal versus tumor tissue (log2 FC = −2.973, t-test p < 0.001).
This table shows molecular features associated with RIPOR3 in patient tissues and cancer cell lines. In patient samples, RIPOR3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RIPOR3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
